financetom
News
World
Environment
Technology
Politics
Retail
Business
Economy
Market summary >
Editors' picks >
News >
World >
Market >
Environment >
Technology >
Metavesco Unveils Transformational OTCfi ACCESS Platform and Strategic Roadmap During High-Impact Livestream Event
Metavesco Unveils Transformational OTCfi ACCESS Platform and Strategic Roadmap During High-Impact Livestream Event
Nov 24, 2025
CUMMING, Ga., Nov. 24, 2025 /PRNewswire/ -- Metavesco, Inc. (OTC: MVCO), a diversified holding company and developer of the OTCfi ecosystem, today announced a series of material updates related to its corporate strategy, capital structure, and development roadmap for its OTCfi ecosystem during a livestream broadcast hosted by CEO Ryan Schadel. The full livestream is available for replay here: https://x.com/CRyanSchadel/status/1992730226263310480?s=20 During...
GEP NAMED THE CLEAR LEADER IN EVEREST GROUP'S 'AGENTIC AI APPLICATIONS IN PROCUREMENT'
GEP NAMED THE CLEAR LEADER IN EVEREST GROUP'S 'AGENTIC AI APPLICATIONS IN PROCUREMENT'
Nov 24, 2025
Cements GEP's leadership in applying AI agents to automate procurement and turn it into a strategic growth leverCites GEP's unmatched vision, maturity, adoption, and ecosystem strength in agentic AI for procurementCLARK, N.J., Nov. 24, 2025 /PRNewswire/ -- GEP®, a leading provider of AI-driven procurement and supply chain software and services for Fortune 500 and Global 2000 enterprises worldwide, announced that that Everest Group...
GE HealthCare’s Photonova™ Spectra with Deep Silicon reimagines photon-counting CT to see more, know more and achieve more
GE HealthCare’s Photonova™ Spectra with Deep Silicon reimagines photon-counting CT to see more, know more and achieve more
Nov 24, 2025
Photonova Spectrai is the first in the next generation of spectral photon counting CT systems with 8-bins of energy resolution, powered by GE HealthCare’s proprietary Deep Silicon detector technology. The new 510(k) pending system is designed to simplify workflows with a one universal scan approach – aiming to boost efficiency and reduce complexity across multiple CT exams. Designed for impact...
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
Nov 24, 2025
Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated PETACH TIKVA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ( NNOX ) , an innovative medical imaging technology company today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI...
Personal Finance >
Politics >
Retail >
Business >
CRH Gains Shareholder Approval for Acquisition of Adbri
CRH Gains Shareholder Approval for Acquisition of Adbri
Jun 14, 2024
05:26 AM EDT, 06/14/2024 (MT Newswires) -- CRH (CRH) said Friday that Adbri's independent shareholders have approved a plan through which it will acquire a majority stake in Adbri for 1.1 billion Australian dollars ($727.3 million). The plan received court approval on Friday. The deal has already secured regulatory approval and is expected to close on July 1, 2024. Under...
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Jun 14, 2024
05:10 AM EDT, 06/14/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was well-tolerated and had a safety profile consistent with other treatments of patients with sickle-cell disease, a blood disorder. The company describes the drug, also called reni-cel, as...
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Jun 14, 2024
05:02 AM EDT, 06/14/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Friday initial data from each of the first two patients dosed with its CABA-201 experimental therapy to treat autoimmune disease in early-to-mid-stage studies showed the treatment was well-tolerated and potentially effective in resetting the immune system. The company said the data showed no serious adverse events, cytokine...
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Jun 14, 2024
05:13 AM EDT, 06/14/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday its Casgevy gene-editing therapy demonstrated clinical benefits in trials in sickle cell disease and transfusion-dependent beta thalassemia. In sickle cell disease, about 92% of evaluable patients were shown to be free from vaso-occlusive crises, or VOCs, for at least 12 months, while 97% of patients with...
Economy >
Cryptocurrency >
Forex >
Copyright 2023-2026 - www.financetom.com All Rights Reserved